Balixafortide

巴利福肽

Report date: 2025/05/13 14:40:52
NME

Base Information

Drug NameBalixafortide
Drug Alias Name巴沙福肽balixafortidumbalixafortidaPOL-6326
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsMetastatic breast cancerMyeloproliferative DisordersMyelodysplastic Syndromes +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPolyphor Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPolyphor Ltd
Inactive CompaniesSpexis AG
Active IndicationsBreast Neoplasms
Inactive IndicationsMetastatic breast cancerMyeloproliferative DisordersMyelodysplastic Syndromes +[8] 

Other Information

ATC CodeN/A
Related LinksN/A